Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, focused on acquiring, developing, and commercialising of medicines for unmet medical needs in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.
Metrics to compare | POLB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPOLBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.2x | −1.2x | −0.6x | |
PEG Ratio | 0.21 | −0.04 | 0.00 | |
Price/Book | 3.0x | 2.0x | 2.6x | |
Price / LTM Sales | - | 2.3x | 3.4x | |
Upside (Analyst Target) | 276.2% | 56.6% | 39.6% | |
Fair Value Upside | Unlock | 3.5% | 5.2% | Unlock |